poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

Aug 3, 2026, 10:21 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ORKA
Source
benzinga
Observed
Aug 3, 2026, 10:21 AM
Checked
Aug 3, 2026, 10:21 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 24, 2026, 8:06 PMSEC EDGAR

    8-K filing — Oruka Therapeutics, Inc. (ORKA)

    Filed: 2026-08-24 AccNo: 0001213900-26-093021 Size: 300 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    ORKA